A narrative review evaluates clinical integration of BRAF-targeted therapy combined with EGFR inhibition, addressing first-line treatment, MMR/MSI status, patient fitness, and sequencing strategies. (J Gastrointest Cancer)
Practical management guidance for BRAF V600E-mutated mCRC in the post-BREAKWATER era
The CRC Digest